|
1
|
Labenz J and Malfertheiner P: Treatment of
uncomplicated reflux disease. World J Gastroenterol. 11:4291–4299.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng Y, Ye Y, Liang D, Guo C and Li L:
Meta-analysis of the efficacy of lansoprazole and omeprazole for
the treatment of H.pylori-associated duodenal ulcer. Int J
Physiol Pathophysiol Pharmacol. 7:158–164. 2015.PubMed/NCBI
|
|
3
|
Wedemeyer RS and Blume H: Pharmacokinetic
drug interaction profiles of proton pump inhibitors: An update.
Drug Saf. 37:201–211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watson C, Zhu L, Guan S, Machen TE and
Forte JG: Reaction of proton pump inhibitors with model peptides
results in novel products. J Pharmacol Sci. 122:213–222. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Solana MJ, López-Herce J, Sánchez A,
Sánchez C, Urbano J, López D and Carrillo A: 0.5 mg/kg versus 1
mg/kg of intravenous omeprazole for the prophylaxis of
gastrointestinal bleeding in critically ill children: A randomized
study. J Pediatr. 162:776–782. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ivey KJ: Mechanisms of nonsteroidal
anti-inflammatory drug-induced gastric damage. Actions of
therapeutic agents. Am J Med. 84:41–48. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abdul Razzak E, Tomás M, Tornero P and
Herrero T: Nine cases of allergy to omeprazole. J Investig Allergol
Clin Immunol. 22:228–230. 2012.PubMed/NCBI
|
|
8
|
Pirson F, Geubel A and Marot L: Late
hypersensitivity to omeprazole and other proton pump inhibitors.
Acta Clin Belg. 67:301–303. 2012.PubMed/NCBI
|
|
9
|
Stefanaki EC, Vovolis V, Letsa I and
Koutsostathis N: Anaphylactic reaction to omeprazole. Am J
Gastroenterol. 103:1581–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reyes Balaguer J, Campos Andreu A and
Hernández Fernández de Rojas D: Anaphylaxis to proton pump
inhibitors. Med Clin (Barc). 128:7992007.(In Spanish). PubMed/NCBI
|
|
11
|
Ramírez E, Cabañas R, Laserna LS, Fiandor
A, Tong H, Prior N, Calderón O, Medrano N, Bobolea I, Frías J and
Quirce S: Proton pump inhibitors are associated with
hypersensitivity reactions to drugs in hospitalized patients: A
nested case-control in a retrospective cohort study. Clin Exp
Allergy. 43:344–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reimer C and Bytzer P: Adverse events
associated with long-term use of proton pump inhibitors. Ugeskr
Laeger. 174:2289–2293. 2012.(In Danish). PubMed/NCBI
|
|
13
|
Shimura S, Hamamoto N, Yoshino N,
Kushiyama Y, Fujishiro H, Komazawa Y, Furuta K, Ishihara S, Adachi
K and Kinoshita Y: Diarrhea caused by proton pump inhibitor
administration: Comparisons among lansoprazole, rabeprazole, and
omeprazole. Curr Ther Res Clin Exp. 73:112–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Femer RE and Allison TR: Omeprazole
overdose. Hum Exp Toxicol. 12:541–542. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Matary W and Dalzell M:
Omeprazole-induced hepatitis. Pediatr Emerg Care. 21:529–530. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Beutler M, Hartmann K, Kuhn M and Gartmann
J: Arthralgias and omeprazole. BMJ. 309:16201994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kraus A and Flores-Suárez LF: Acute gout
associated with omeprazole. Lancet. 345:461–462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Odou P, Martin P, Membré S, Gressier B,
Tamiji L, Dine T, Luyckx MM, Brunet C, Dehee D and Moulron S:
Omeprazole-induced leukopenia. A case report. J Clin Pharm Ther.
24:317–321. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osler T, Cook A, Glance LG, Lecky F,
Bouamra O, Garrett M, Buzas JS and Hosmer DW: The differential
mortality of Glasgow Coma Score in patients with and without head
injury. Injury. April 22–2016.(Epub ahead of print) doi:
10.1016/j.injury.2016.04.016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kasprowicz M, Burzynska M, Melcer T and
Kübler A: A comparison of the full outline of unresponsiveness
(FOUR) score and Glasgow Coma Score (GCS) in predictive modelling
in traumatic brain injury. Br J Neurosurg. 30:211–220. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shiohira H, Yasui-Furukori N, Tateishi T
and Uno T: Chairal assay of omeprazole and metabolites and its
application to a pharmacokinetics related to CYP2C19 genotypes. J
Chromatogr B Analyt Technol Biomed Life Sci. 879:2465–2470. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Serrano D, Torrado S, Torrado-Santiago S
and Gisbert JP: The influence of CYP2C19 genetic polymorphism on
the pharmacokinetics/- pharmacodynamics of proton pump
inhibitor-containing Helicobacter pylori treatments. Curr Drug
Metab. 13:1303–1312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu Z, Liu H, He L, Ma Y, Song H, Bai W
and Yu M: Proton pump inhibitor-induced exfoliative dermatitis: A
case report. Exp Ther Med. 11:543–546. 2016.PubMed/NCBI
|
|
24
|
Hood W, McJunkin B, Warnock A, Girme A,
Smith N and Robinson B: Proton pump inhibitor prescribing and costs
in a large outpatient clinic. W V Med J. 110:16–21. 2014.PubMed/NCBI
|
|
25
|
Mouterde O, Bellaïche M, Dumant C and
Mallet E: Gastroesophageal reflux and proton pump inhibitors:
Panacea or prescription abuse? Arch Pediatr. 17:739–740. 2010.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forgacs I and Loganayagam A:
Overprescribing proton pump inhibitors. BMJ. 336:2–3. 2008.
View Article : Google Scholar : PubMed/NCBI
|
